0
0
An antibody drug from pharmaceutical company AstraZeneca provides good protection against corona disease, according to clinical tests. The drug, AZD7442 – a combination of two long-acting antibodies – is specifically designed for people for whom vaccination is not particularly suitable for certain reasons. The drug reduced the risk of symptomatic Covid-19 by 77 percent in tests from a Phase III clinical trial, AstraZeneca said Friday (Aug. 20) in London. None of the subjects given the drug became severely ill or died. In the comparison group, which received a placebo, there were three severe covid cases and two deaths. The antibody drug is injected in a single dose into the muscle and is thus said to be easy to administer.
- source: news agencies/picture: pixabay.com
This post has already been read 546 times!
